GW Pharmaceuticals also announced in November that it had begun human trials of a CBD-rich cannabis drug for the treatment of pediatric epilepsy.
Big Pharma company, GW Pharmaceuticals, has received approval on a patent giving them the exclusive rights to treat cancer patients with marijuana.
GW Pharmaceuticals has been issued a Notice of Allowance from the U.S. Patent Office for a patent applications involving the use of THC and CBD – the two main chemicals in marijuana.
Leafscience.com reports: Once a patent application is deemed a genuine invention, the Patent Office sends a Notice of Allowance that outlines the fees involved with final approval.
Specifically, the company provides this description of the patent:
“The subject patent specifically covers a method for treating glioma in a human using a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) wherein the cannabinoids are in a ratio of from 1:1 to 1:20 (THC:CBD) with the intent to reduce cell viability, inhibit cell growth or reduce tumor volume.”
Filed in 2009, GW’s patent application lists Otsuka Pharmaceutical as a collaborator and…
View original post 161 more words